Literature DB >> 33572350

The Vault Nanoparticle: A Gigantic Ribonucleoprotein Assembly Involved in Diverse Physiological and Pathological Phenomena and an Ideal Nanovector for Drug Delivery and Therapy.

Gianni Frascotti1, Elisabetta Galbiati1, Matteo Mazzucchelli1, Maria Pozzi1, Lucia Salvioni1, Jacopo Vertemara1, Paolo Tortora1.   

Abstract

The vault nanoparticle is a eukaryotic ribonucleoprotein complex consisting of 78 individual 97 kDa-"major vault protein" (MVP) molecules that form two symmetrical, cup-shaped, hollow halves. It has a huge size (72.5 × 41 × 41 nm) and an internal cavity, wherein the vault poly(ADP-ribose) polymerase (vPARP), telomerase-associated protein-1 (TEP1), and some small untranslated RNAs are accommodated. Plenty of literature reports on the biological role(s) of this nanocomplex, as well as its involvement in diseases, mostly oncological ones. Nevertheless, much has still to be understood as to how vault participates in normal and pathological mechanisms. In this comprehensive review, current understanding of its biological roles is discussed. By different mechanisms, vault's individual components are involved in major cellular phenomena, which result in protection against cellular stresses, such as DNA-damaging agents, irradiation, hypoxia, hyperosmotic, and oxidative conditions. These diverse cellular functions are accomplished by different mechanisms, mainly gene expression reprogramming, activation of proliferative/prosurvival signaling pathways, export from the nucleus of DNA-damaging drugs, and import of specific proteins. The cellular functions of this nanocomplex may also result in the onset of pathological conditions, mainly (but not exclusively) tumor proliferation and multidrug resistance. The current understanding of its biological roles in physiological and pathological processes should also provide new hints to extend the scope of its exploitation as a nanocarrier for drug delivery.

Entities:  

Keywords:  major vault protein (MVP); multidrug resistance (MDR); nanomedicine; vault nanoparticle

Year:  2021        PMID: 33572350      PMCID: PMC7916137          DOI: 10.3390/cancers13040707

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  222 in total

1.  Structural insights into RNA quality control: the Ro autoantigen binds misfolded RNAs via its central cavity.

Authors:  Adam J Stein; Gabriele Fuchs; Chunmei Fu; Sandra L Wolin; Karin M Reinisch
Journal:  Cell       Date:  2005-05-20       Impact factor: 41.582

Review 2.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

3.  Solution structure of a two-repeat fragment of major vault protein.

Authors:  Guennadi Kozlov; Olga Vavelyuk; Ovidiu Minailiuc; Denis Banville; Kalle Gehring; Irena Ekiel
Journal:  J Mol Biol       Date:  2005-12-07       Impact factor: 5.469

4.  Synthesis and assembly of human vault particles in yeast.

Authors:  Meng Wang; Valerie A Kickhoefer; Leonard H Rome; Oliver K Foellmer; Shaily Mahendra
Journal:  Biotechnol Bioeng       Date:  2018-09-25       Impact factor: 4.530

Review 5.  Development of the vault particle as a platform technology.

Authors:  Leonard H Rome; Valerie A Kickhoefer
Journal:  ACS Nano       Date:  2012-12-31       Impact factor: 15.881

Review 6.  Sp1 transcription factor: A long-standing target in cancer chemotherapy.

Authors:  Carolina Vizcaíno; Sylvia Mansilla; José Portugal
Journal:  Pharmacol Ther       Date:  2015-05-08       Impact factor: 12.310

Review 7.  Selected glimpses into the activation and function of Src kinase.

Authors:  J D Bjorge; A Jakymiw; D J Fujita
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

8.  Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics.

Authors:  Marieke H Mossink; Arend van Zon; Erna Fränzel-Luiten; Martijn Schoester; Valerie A Kickhoefer; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

9.  The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.

Authors:  Lei Li; Guo-Dong Zhao; Zhe Shi; Li-Li Qi; Li-Yuan Zhou; Ze-Xian Fu
Journal:  Oncol Lett       Date:  2016-09-09       Impact factor: 2.967

10.  Unbiased analysis of senescence associated secretory phenotype (SASP) to identify common components following different genotoxic stresses.

Authors:  Servet Özcan; Nicola Alessio; Mustafa B Acar; Eda Mert; Fatih Omerli; Gianfranco Peluso; Umberto Galderisi
Journal:  Aging (Albany NY)       Date:  2016-07       Impact factor: 5.682

View more
  5 in total

Review 1.  Small but Powerful: The Human Vault RNAs as Multifaceted Modulators of Pro-Survival Characteristics and Tumorigenesis.

Authors:  Stefano Gallo; EunBin Kong; Iolanda Ferro; Norbert Polacek
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

Review 2.  Supramolecular assembly of protein building blocks: from folding to function.

Authors:  Nam Hyeong Kim; Hojae Choi; Zafar Muhammad Shahzad; Heesoo Ki; Jaekyoung Lee; Heeyeop Chae; Yong Ho Kim
Journal:  Nano Converg       Date:  2022-01-13

3.  Symmetry disruption commits vault particles to disassembly.

Authors:  Pablo Guerra; María González-Alamos; Aida Llauró; Arnau Casañas; Jordi Querol-Audí; Pedro J de Pablo; Núria Verdaguer
Journal:  Sci Adv       Date:  2022-02-09       Impact factor: 14.136

4.  Role of Fasciola hepatica Small RNAs in the Interaction With the Mammalian Host.

Authors:  Santiago Fontenla; Mauricio Langleib; Eduardo de la Torre-Escudero; Maria Fernanda Domínguez; Mark W Robinson; José Tort
Journal:  Front Cell Infect Microbiol       Date:  2022-01-20       Impact factor: 5.293

5.  Major vault protein attenuates cardiomyocyte injury in doxorubicin-induced cardiomyopathy through activating AKT.

Authors:  Yu Qi; Jianzhou Chen; Junfeng Duan; Lina Kang; Kun Wang; Ziwei Chen; Biao Xu; Rong Gu
Journal:  BMC Cardiovasc Disord       Date:  2022-03-04       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.